v3.19.3.a.u2

Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Jun. 30, 2018 option | Oct. 31, 2017 | Jan. 31, 2016 | Mar. 31, 2013 USD ($) milestone option | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) option | Mar. 31, 2018 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Jan. 01, 2019 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | $ 249,500,000 |  |  |  |  |  |  |  | $ 249,500,000 |  |  |  |
Deferred revenue |  |  |  |  | 199,528,000 |  |  |  | $ 240,924,000 |  |  |  | 199,528,000 | $ 240,924,000 |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  | 60,209,000 |  |  |  |
Collaboration revenue |  |  |  |  | 14,055,000 | $ 17,046,000 | $ 13,083,000 | $ 16,025,000 | 35,421,000 | $ 41,757,000 | $ 28,851,000 | $ 29,039,000 | 60,209,000 | 135,068,000 | $ 205,825,000 |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  | 42,803,000 |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  | 42,803,000 | 76,519,000 | 146,953,000 |  |
Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 400,000,000
Increase to the transaction price |  |  |  |  |  | 1,000,000 |  |  |  |  |  |  | 1,800,000 |  |  |  |
Change in estimate of variable consideration |  |  |  |  |  |  |  |  |  |  |  |  | 800,000 |  |  |  |
Deferred revenue |  |  |  |  | 73,700,000 |  |  |  | 115,600,000 |  |  |  | 73,700,000 | 115,600,000 |  |  | 75,700,000
Combined 2018 AZ Agreements | Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer, excluding assessed tax |  |  |  |  |  |  |  |  |  |  |  |  | 4,300,000 | 45,400,000 | $ 30,000,000 |  |
2013 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 240,000,000
Number of options to develop candidates | option |  |  |  | 40 |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payments |  |  |  | $ 240,000,000 |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |
Estimated arrangement consideration |  |  |  | $ 180,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of milestones | milestone |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Termination period |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |
2013 AZ Agreements | VEGF-A product (AZD8601) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront cash payments |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000 |  |  |
2013 AZ Agreements | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Earn-out payments |  |  |  | 12.00% |  |  |  |  |  |  |  |  |  |  |  |  |
2013 AZ Agreements | Development Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  | $ 100,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
2013 AZ Agreements | Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  | 100,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
2013 AZ Agreements | Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  | $ 200,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
VEGF Exercise 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 55,100,000
Increase to the transaction price |  |  |  |  |  | $ 2,300,000 |  |  |  |  |  |  | 2,800,000 |  |  |  |
Change in estimate of variable consideration |  |  |  |  |  |  |  |  |  |  |  |  | 500,000 |  |  |  |
Deferred revenue |  |  |  |  | 41,200,000 |  |  |  | $ 41,200,000 |  |  |  | 41,200,000 | 41,200,000 |  |  | 37,100,000
2016 AZ Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination period |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Suspension period |  |  | 12 months |  |  |  |  |  |  |  |  |  |  |  |  |  |
2016 AZ Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalties |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
2016 AZ Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalties at default rate |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalties |  |  | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
2017 AZ Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination period |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Suspension period |  | 12 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  | 0 | $ 600,000 |  |  |
2017 AZ Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalties |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2017 AZ Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalties |  | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2018 A&R Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options to develop candidates | option | 40 |  |  |  |  |  |  |  |  |  | 40 |  |  |  |  |  |
Termination period | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Variable Consideration | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 160,000,000
Variable Consideration | VEGF Exercise 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,100,000
Estimated Reimbursement | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 40,000,000
Estimated Reimbursement | Combined 2018 AZ Agreements | Toxicity Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 60,000,000 |  |  |  |  |  |  |  | 60,000,000 |  |  |  |
Fixed Payments | VEGF Exercise 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 40,000,000
Milestone Payments | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 120,000,000
Milestone Payments | Combined 2018 AZ Agreements | Toxicity Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000
Milestone Payments | Combined 2018 AZ Agreements | Competition Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000
Milestone Payments | VEGF Exercise 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000
Option Exercise Fee | VEGF Exercise 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000
Combined 2018 AZ Agreement Performance Obligation | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 293,200,000 |  |  |  |  |  |  |  | 293,200,000 |  |  |  |
IL12 Performance Obligation | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 8,100,000 |  |  |  |  |  |  |  | 8,100,000 |  |  |  |
Oncology Development Target Performance Obligation | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 8,100,000 |  |  |  |  |  |  |  | 8,100,000 |  |  |  |
Development And Commercialization License And Manufacturing Obligations For IL12 | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 90,700,000 |  |  |  |  |  |  |  | 90,700,000 |  |  |  |
Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target | Combined 2018 AZ Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | $ 1,600,000 |  |  |  |  |  |  |  | $ 1,600,000 |  |  |  |

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent
Namespace Prefix: | mrna_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Maximum Amount + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Options + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent
Namespace Prefix: | mrna_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent
Namespace Prefix: | mrna_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Termination Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_VEGFAProductAZD8601Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_EstimatedReimbursementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_ToxicityMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_FixedPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CompetitionMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_OptionExerciseFeeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_Combined2018AZAgreementPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_OncologyDevelopmentTargetPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |